AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22528284
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DARB) 1 mg/kg IV immediately before surgery
Trial: 22529273
Drug: Standard perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard perioperative care with intraoperative morphine
Trial: 22537988
Drug: 2-dose MenC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose MenC vaccine (given at 2 and 4 months)
Trial: 22537988
Drug: 1-dose MenC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-dose MenC vaccine (given at 2 months)
Trial: 22537988
Drug: All subjects
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects after the 12 month MenC dose
Trial: 22539091
Drug: Tasisulam sodium
RxNorm normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasisulam sodium (420 μg/mL) administered intravenously on day 1 of 21-day cycles
Trial: 22540954
Drug: 2.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mg/kg intravenous artesunate
Trial: 22541066
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus 3-AP (96 mg/m(2) for 4 days, with cisplatin at 25 mg/m(2) on days 2 and 3)
Trial: 22541066
Drug: 3-AP (96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-AP (96 mg/m(2))
Trial: 22541660
Drug: Cataract surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cataract surgery with intact posterior capsules, manual posterior capsulorrhexis without anterior limbal vitrectomy, and anterior limbal vitrectomy
Trial: 22542159
Drug: Systemic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic infusion of bone marrow mesenchymal stem cells (BMMSCs)
Trial: 22543217
Drug: Adaptive planning
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adaptive planning (replanning of radiation therapy)
Trial: 22543217
Drug: Nonadaptive planning
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nonadaptive planning (original treatment plans)
Trial: 22546242
Drug: Ezatiostat 2000
RxNorm normalized name: Ezatiostat
DrugBank: Ezatiostat (DB05460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezatiostat 2000 mg/day + Lenalidomide 10 mg (days 1-21 of a 28-day cycle)
Trial: 22546242
Drug: Ezatiostat 2500
RxNorm normalized name: Ezatiostat
DrugBank: Ezatiostat (DB05460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezatiostat 2500 mg/day + Lenalidomide 10 mg (days 1-21 of a 28-day cycle)
Trial: 22547163
Drug: Salirasib 200-800
RxNorm normalized name: Salirasib
DrugBank: Salirasib (DB12681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salirasib 200-800 mg orally (PO) twice daily (bid) for 21 days every 28 days in combination with gemcitabine.
Trial: 22547163
Drug: Salirasib administered
RxNorm normalized name: Salirasib
DrugBank: Salirasib (DB12681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salirasib administered alone and in combination with gemcitabine.
Trial: 22547163
Drug: Gemcitabine (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (standard dose schedule).
Trial: 22550086
Drug: Amantadine sulfate
RxNorm normalized name: amantadine sulfate
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine sulfate 6.3 ± 0.87 mg/kg/d for 8 weeks
Trial: 22554343
Drug: IRIS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRIS plus bevacizumab (S-1 40-60 mg twice daily on Days 1 to 14, irinotecan 100 mg/m² and bevacizumab 5 mg/kg on Days 1 and 15 of a 28-day cycle)
Trial: 22555973
Drug: Intravenous carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous carfilzomib 20 mg/m(2) for all treatment cycles (Cohort 1)
Trial: 22555973
Drug: Intravenous carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous carfilzomib 20 mg/m(2) for cycle 1 and then 27 mg/m(2) for all subsequent cycles (Cohort 2)
Trial: 22556318
Drug: QuantiFERON TB
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QuantiFERON TB Gold In-Tube assay (QFT-GIT) monthly for 1 year
Trial: 22558101
Drug: DOTAP:cholesterol nanoparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOTAP:cholesterol nanoparticles encapsulating a TUSC2 expression plasmid (DOTAP:chol-TUSC2) administered intravenously every 3 weeks at escalating doses (0.01 to 0.09 mg/kg)
Trial: 22559192
Drug: Low-frequency deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency deep TMS (1 Hz for 10 min) applied over the left temporoparietal cortex, 10 daily treatment sessions at 110% of the motor threshold.
Trial: 22559192
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (placebo) according to patient randomization.
Trial: 22560543
Drug: High-dose thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thoracic radiation (61.2 Gy over 5 weeks, daily 1.8-Gy fractions on days 1-22, then twice-daily 1.8-Gy fractions on days 23-33) with concurrent chemotherapy (Cisplatin 60 mg/m² IV on day 1, Etoposide 120 mg/m² IV on days 1-3 and days 22-24).
Trial: 22560543
Drug: High-dose thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thoracic radiation with concurrent chemotherapy.
Trial: 22563089
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m(2) infused weekly on days 56, 63, 70, and 77 after transplantation)
Trial: 22565291
Drug: Intrapartum antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapartum antibiotic prophylaxis (10.5% of women received this intervention)
Trial: 22565291
Drug: Low birth
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low birth weight (<1500 g)
Trial: 22566506
Drug: Tacrolimus (0.15-0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (0.15-0.30 mg/kg per day in 2 divided oral doses) and prednisone (60 mg per day, tapered off during 1 to 4 weeks)
Trial: 22566605
Drug: Decitabine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (20 mg/m² intravenously on days 1-10) plus bortezomib (escalated up to the target 1.3 mg/m² on days 5, 8, 12, and 15)
Trial: 22566747
Drug: High-adherence insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-adherence insulin
Trial: 22568777
Drug: DIGS software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIGS software insulin dosage adjustments
Trial: 22570147
Drug: Efatutazone at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efatutazone at doses ranging from 0.10 to 1.15 mg PO twice daily for 6 weeks
Trial: 22570147
Drug: Efatutazone at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efatutazone at the recommended phase 2 dose of 0.5 mg PO twice daily
Trial: 22573483
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of RAAS blockade and diuretics
Trial: 22573483
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or more diuretics
Trial: 22573483
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with diuretics and RAAS blockade
Trial: 22574715
Drug: In-patient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-patient treatment program based on physical exercise and a balanced diet
Trial: 22576338
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI regimen (irinotecan 180 mg/m² i.v. on day 1, leucovorin 200 mg/m² i.v. on days 1 and 2, 5-FU 400 mg/m² i.v. bolus on days 1 and 2, and 5-FU 600 mg/m² i.v. by ci for 22 h on days 1 and 2, repeated every 2 weeks)
Trial: 22577154
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) treatment
Trial: 22579160
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment with tapering and discontinuation of risperidone long-acting injection over 6 weeks, followed by reinstitution of oral risperidone or risperidone long-acting injection upon symptom recurrence.
Trial: 22579160
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group not explicitly mentioned, but refers to the absence of continuous treatment after 2 years.
Trial: 22580120
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation therapy (54 Gy, 5-fluouracil-based)
Trial: 22583335
Drug: Rilonacept (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilonacept (320 mg loading dose followed by 160 mg weekly for up to 1 year)
Trial: 22586008
Drug: Laxative-free computed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative-free computed tomographic colonography (CTC)
Trial: 22589436
Drug: Oral minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral minocycline 100 mg twice daily for 6 months
Trial: 22590502
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg DNA
Trial: 22590502
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg DNA
Trial: 22590502
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg DNA
Trial: 22592608
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Trial: 22592608
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of blinatumomab
Trial: 23643595
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of copeptin and cTnI
Trial: 22594491
Drug: GRAZAX(®) (Phleum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRAZAX(®) (Phleum Pratense, 75,000 SQ-T/2,800 BAU), administered as one tablet daily for at least 4 months before the pollen season and maintained throughout the season.
Trial: 22595848
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation therapy followed by total mesorectal excision
Trial: 22599356
Drug: Targeted hypoglossal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted hypoglossal neurostimulation (THN) therapy with the aura6000™ System
Trial: 22605616
Drug: Tivantinib (ARQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib (ARQ 197) 120, 240, 360, and 480 mg BID plus erlotinib 150 mg QD
Trial: 22605616
Drug: Tivantinib (ARQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib (ARQ 197) 360 mg BID plus erlotinib 150 mg QD
Trial: 22605650
Drug: Tivantinib 120
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib 120 mg orally twice daily, then 360 mg twice daily per protocol amendment
Trial: 22608106
Drug: Exenatide 10
RxNorm normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 μg BID
Trial: 22608261
Drug: Individualised accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised accelerated radiotherapy (INDAR) with a mean lung dose (MLD) of 19 Gy, spinal cord 54 Gy, brachial plexus 66 Gy, central structures 74 Gy, total dose between 51 and 69 Gy delivered in 1.5 Gy BID up to 45 Gy followed by 2 Gy QD, starting at the 2nd or 3rd course of chemotherapy
Trial: 22608338
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg twice daily (recommended phase 2 dose)
Trial: 22608338
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg twice daily (in patients with Val600Glu BRAF-mutant melanoma)
Trial: 22608338
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg twice daily (in patients with Val600 BRAF-mutant melanoma)
Trial: 22615311
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 30-μg 2009 Novartis pH1N1 monovalent vaccine (Fluvirin)
Trial: 22615311
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of double-strength pH1N1 vaccine
Trial: 22615340
Drug: Biological antiplatelet
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological antiplatelet drug responsiveness (specific and aggregation-based assays)
Trial: 22619884
Drug: Resistance prevalence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance prevalence for other antibiotics
Trial: 22621246
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA supplementation (fish oil capsules providing 1.14g DHA and 1.56g EPA for 12 weeks)
Trial: 22622425
Drug: Anti-IL-17 receptor
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti-IL-17 receptor antibody AMG 827
Trial: 22622497
Drug: At-home short
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home short daily hemodialysis (6 times per week)
Trial: 22623056
Drug: Quality control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality control samples at 0.0600, 2.00 and 8.00 ng/mL
Trial: 22626819
Drug: Intraoperative PAI-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative PAI-1 (plasminogen activator inhibitor-1)
Trial: 22627182
Drug: Pitavastatin 4
RxNorm normalized name: PITAVASTATIN 4MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4 mg alone
Trial: 22627182
Drug: Pitavastatin 4
RxNorm normalized name: PITAVASTATIN 4MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4 mg with lopinavir/ritonavir 400 mg/100 mg
Trial: 22627678
Drug: Midostaurin 50-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 50-mg twice-daily dose schedule
Trial: 22627678
Drug: Midostaurin 100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin 100-mg twice-daily dose schedule
Trial: 22627678
Drug: Midostaurin in
RxNorm normalized name: Product containing midostaurin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin in combination with standard chemotherapy
Trial: 22633255
Drug: First model
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First model (age, duration of infertility, insulin/glucose ratio)
Trial: 22633265
Drug: GnRH agonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists with serum P levels ≥ 2.0 ng/mL
Trial: 22633265
Drug: GnRH agonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists with serum P levels <1.5 ng/mL
Trial: 22633265
Drug: GnRH agonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists with serum P levels 1.5-1.99 ng/mL
Trial: 22633322
Drug: Na-ASP-2 vaccine
RxNorm normalized name: sodium lauroyl aspartate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na-ASP-2 vaccine
Trial: 22634437
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine 160U (only for children)
Trial: 22634437
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine 320U
Trial: 22634437
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine 640U
Trial: 22634437
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (all doses)
Trial: 22634437
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (one dose)
Trial: 22638007
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral therapy (CBT) for depression
Trial: 22639293
Drug: Lipid infusion
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid infusion (20% Intralipid at 90 ml/h)
Trial: 22639293
Drug: Glycerol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol infusion (2.25 g/100 ml at 90 ml/h)
Trial: 22640652
Drug: Seasonal flu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal flu vaccine (SFV) - 1 dose, Mutagrip®
Trial: 22640652
Drug: A/H1N1 flu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/H1N1 flu vaccine (HFV) - 2 doses at a 3-week interval, Panenza®
Trial: 22640652
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines (SFV and HFV)
Trial: 22643560
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg every 3 weeks) and Erlotinib (150 mg daily)
Trial: 22645182
Drug: Dasatinib (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (first-line therapy)
Trial: 22647431
Drug: Etanercept therapy
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept therapy (anti-TNF) for 12 weeks
Trial: 22647519
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV infusion of adenosine via the forearm vein (140 μg/min/kg)
Trial: 22647519
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV infusion of adenosine via the femoral vein (140 μg/min/kg)
Trial: 22647519
Drug: Intracoronary bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary bolus injection of adenosine
Trial: 22647519
Drug: Additional bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional bolus injection of adenosine during IV infusion
Trial: 22647519
Drug: Both routes
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both routes of adenosine infusion (femoral vs. forearm)
Trial: 22648179
Drug: Weekly dosing
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dosing of trastuzumab emtansine (T-DM1) at 2.4 mg/kg
Trial: 22648179
Drug: Weekly dosing
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dosing of trastuzumab emtansine (T-DM1)
Trial: 22651703
Drug: Vemurafenib and
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib and GDC-0973 combination
Trial: 22651703
Drug: Vemurafenib in
RxNorm normalized name: Product containing vemurafenib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib in mice with drug-resistant A375 xenografts
Trial: 22651703
Drug: Vemurafenib and
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib and GDC-0973 combination efficacy
Trial: 22652104
Drug: 3-dimensional conformal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dimensional conformal external beam accelerated partial breast irradiation (3D-APBI) at 32 Gy delivered in 8 twice-daily fractions
Trial: 22653976
Drug: Bortezomib combined
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib combined with chemotherapy
Trial: 22653976
Drug: Bortezomib combined
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib combined with chemotherapy and prophylactic antibiotics (vancomycin, levofloxacin, voriconazole)
Trial: 22655593
Drug: Encapsulated cell
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated cell biodelivery (ECB) implants delivering nerve growth factor (NGF)